ITM Isotope Technologies Munich SE Revenue and Competitors
Estimated Revenue & Valuation
- ITM Isotope Technologies Munich SE's estimated annual revenue is currently $91.7M per year.
- ITM Isotope Technologies Munich SE's estimated revenue per employee is $201,000
Employee Data
- ITM Isotope Technologies Munich SE has 456 Employees.
- ITM Isotope Technologies Munich SE grew their employee count by 39% last year.
ITM Isotope Technologies Munich SE's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Head Corporate Quality | Reveal Email/Phone |
3 | VP, Head Project Management Organization (PMO) | Reveal Email/Phone |
4 | Head Quality Control | Reveal Email/Phone |
5 | Head Microbiology QC (interim) | Reveal Email/Phone |
6 | Head Corporate Quality Systems and Services | Reveal Email/Phone |
7 | Head Manufacturing Science & Technology | Reveal Email/Phone |
8 | VP Research and Development | Reveal Email/Phone |
9 | VP Global Commercial Operations - Radiopharmaceuticals | Reveal Email/Phone |
10 | Head Global Medical Affairs | Reveal Email/Phone |
ITM Isotope Technologies Munich SE Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $91.7M | 456 | 39% | N/A | N/A |
What Is ITM Isotope Technologies Munich SE?
PASSION FOR PRECISION. ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radioisotopes and generator platform for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine tumors, glioblastoma, osteosarcoma and bone metastases, as well as folate receptor α positive tumors like lung, ovarian or breast cancer. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve treatment outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology. For more information please visit: www.itm-radiopharma.com. Please see our Community Guidelines: https://isotope-technologies-munich.com/service/community-guidelines
keywords:N/AN/A
Total Funding
456
Number of Employees
$91.7M
Revenue (est)
39%
Employee Growth %
N/A
Valuation
N/A
Accelerator